Pär Hallberg

Dr. Pär Hallberg

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Gastroenterology
Verified
Journal Article
Open access
PDF file
PNPaola Nicoletti
Paola Nicoletti
GAGuruprasad Aithal
Guruprasad Aithal
EBEinar S. Bjornsson
Einar S. Bjornsson
RARaul J. Andrade
Raul J. Andrade
ASAshley Sawle
Ashley Sawle
ADAnn Daly
Ann Daly
Background & Aims We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors. Methods We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls. The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274). The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America. For the GWAS, we included only cases with patients of European ancestry associated with a particular drug (but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. After the discovery analysis was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI associated with various drugs. Results We associated DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9−3.8; P = 2.4 × 10−8) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6−2.5; P = 9.7 × 10−9). The association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI. The variant on chromosome 2 was associated with DILI from a variety of drugs. Further phenotypic analysis indicated that the association between DILI and A*33:01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was associated with cholestatic and mixed DILI as well as hepatocellular DILI. We identified an association between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor containing gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6−2.7; P = 4.8 × 10−9). We did not associate any specific drug classes with genetic polymorphisms, except for statin-associated DILI, which was associated with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0−9.5; P = 7.1 × 10−9). We validated the association between A*33:01 terbinafine- and sertraline-induced DILI. We could not validate the association between DILI and rs72631567, rs28521457, or rs116561224. Conclusions In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. We identified polymorphisms that appear to be associated with DILI from statins, as well as 2 non−drug-specific risk factors.

19 June 2010 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SSSofie Schwan
Sofie Schwan
ASAnders Sundström
Anders Sundström
ESElisabet Stjernberg
Elisabet Stjernberg
EHEbba Hallberg
Ebba Hallberg
PHPär Hallberg
Pär Hallberg

1 May 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
PNPaola Nicoletti
Paola Nicoletti
KAKaren Abramson
Karen Abramson
RARaul J. Andrade
Raul J. Andrade
EBEinar S. Bjornsson
Einar S. Bjornsson
MWMia Wadelius
Mia Wadelius

8 August 2007 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
PHPär Hallberg
Pär Hallberg
JLJohan Lindbäck
Johan Lindbäck
BLBertil Lindahl
Bertil Lindahl
USUlf Stenestrand
Ulf Stenestrand
HMHåkan Melhus
Håkan Melhus
FGfor the RIKS-HIA group
for the RIKS-HIA group

1 February 2005 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
PHPär Hallberg
Pär Hallberg
VSViktoria Sjöblom
Viktoria Sjöblom
Mood and anxiety disorders are common in women during their childbearing years. The prevalence of depression has been reported to be between 10% and 16% during pregnancy. The use of selective serotonin reuptake inhibitors during pregnancy or lactation is, to date, not promoted because of lack of safety documentation. However, the off-label use of these drugs has been common for several years. In the treatment of mood and anxiety disorders during pregnancy, the serotonin reuptake inhibitors are often preferred over tricyclic antidepressants because of their relatively few adverse effects and safety in overdose. This has created concern among women planning pregnancies and pregnant women, as well as among their families and physicians. Several studies and reports of the use of serotonin reuptake inhibitors during both pregnancy and lactation have been published and advanced our knowledge. We here review and discuss those studies which have been published so far on this subject.

31 December 2016 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
PFPpl Fung
Ppl Fung
GBGiorgio Bedogni
Giorgio Bedogni
ABA Bedogni
A Bedogni
APA Petrie
A Petrie
SPStephen Porter
Stephen Porter
SFStefano Fedele
Stefano Fedele